Bernstein has revised upwards its price target for Abbott Laboratories (ABT, Financial), setting it at $144, an increase from the previous $138. The firm continues to rate Abbott shares as Outperform, indicating confidence in the company's market trajectory.
This adjustment comes in response to Abbott's robust quarterly performance and its ability to maintain its financial guidance, even with an additional $350 million impact from tariffs. This highlights the company's resilience in navigating economic challenges while continuing to perform strongly.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 23 analysts, the average target price for Abbott Laboratories (ABT, Financial) is $140.41 with a high estimate of $158.00 and a low estimate of $111.34. The average target implies an upside of 8.25% from the current price of $129.70. More detailed estimate data can be found on the Abbott Laboratories (ABT) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, Abbott Laboratories's (ABT, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Abbott Laboratories (ABT, Financial) in one year is $118.41, suggesting a downside of 8.7% from the current price of $129.7. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Abbott Laboratories (ABT) Summary page.
